stocks logo

CRDF

Cardiff Oncology Inc
$
4.140
-0.15(-3.497%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
4.520
Open
4.300
VWAP
4.35
Vol
2.04M
Mkt Cap
275.42M
Low
4.130
Amount
8.87M
EV/EBITDA(TTM)
--
Total Shares
44.74M
EV
205.51M
EV/OCF(TTM)
--
P/S(TTM)
388.13
Cardiff Oncology, Inc. is a clinical-stage biotechnology company. It is leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with unmet medical need. It is focused on clinical programs in indications, such as RAS-mutated metastatic colorectal cancer (mCRC), and in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), and triple negative breast cancer (TNBC). Its lead drug candidate, Onvansertib, is an oral, small-molecule drug candidate that is highly specific for PLK1 inhibition with a 24-hour half-life. It has other ongoing and planned clinical trials of onvansertib: one trial (CRDF-004) in first-line treatment in patients with RAS-mutated mCRC, and investigator-initiated trials in first-line mPDAC, relapsed SCLC and unresectable locally advanced or metastatic TNBC.
Show More

Market Estimates

Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
100.00K
-38.65%
--
--
100.00K
-39.39%
--
--
100.00K
-33.77%
--
--
Estimates Revision
The market is revising Upward the revenue expectations for Cardiff Oncology, Inc. (CRDF) for FY2025, with the revenue forecasts being adjusted by 19.8% over the past three months. During the same period, the stock price has changed by 42.76%.
Revenue Estimates for FY2025
Revise Upward
up Image
+19.8%
In Past 3 Month
Stock Price
Go Up
up Image
+42.76%
In Past 3 Month
6 Analyst Rating
up Image
153.62% Upside
Wall Street analysts forecast CRDF stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRDF is 10.50 USD with a low forecast of 3.50 USD and a high forecast of 18.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
1 Hold
0 Sell
Strong Buy
up Image
153.62% Upside
Current: 4.140
sliders
Low
3.50
Averages
10.50
High
18.00
Ladenburg
Kevin Degeeter
Buy
initiated
$19
2025-07-08
Reason
Ladenburg analyst Kevin Degeeter initiated coverage of Cardiff Oncology with a Buy rating and $19 price target. The firm, which sees potential for onvansertib to become a new treatment option for first-line KRAS and NRAS mutated colorectal cancer, expects a planned update on July 29 to clarify the tolerability profile and potentially enable selection of an onvansertib dose for Phase 3 development.
Jefferies
Hold
initiated
$3.50
2025-06-24
Reason
Jefferies initiated coverage of Cardiff Oncology with a Hold rating and $3.50 price target. The company's onvansertib has shown promising early data in 1L RAS mutations metastatic colorectal cancer, but the data are early and the drug's mechanism of action is risky with prior failed studies, the analyst tells investors in a research note. The firm believes catalysts for rest of year may not provide adequate efficacy insight. It plans to reassess the Hold rating post the July 29 data update.
H.C. Wainwright
H.C. Wainwright
Buy
maintain
$18
2025-06-19
Reason
H.C. Wainwright
Robert Burns
Buy
upgrade
$17 -> $18
2025-05-09
Reason
H.C. Wainwright analyst Robert Burns raised the firm's price target on Cardiff Oncology to $18 from $17 and keeps a Buy rating on the shares following the Q1 report.
HC Wainwright & Co.
Robert Burns
Strong Buy
Maintains
$13 → $17
2025-02-28
Reason
Piper Sandler
Joseph Catanzaro
Buy
Maintains
$7 → $10
2024-12-13
Reason

Valuation Metrics

The current forward P/E ratio for Cardiff Oncology Inc (CRDF.O) is -4.62, compared to its 5-year average forward P/E of -5.88. For a more detailed relative valuation and DCF analysis to assess Cardiff Oncology Inc 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-5.88
Current PE
-4.62
Overvalued PE
0.83
Undervalued PE
-12.59

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
813.32
Current PS
636.29
Overvalued PS
1553.35
Undervalued PS
73.29

Financials

Annual
Quarterly
FY2025Q1
YoY :
-46.83%
109.00K
Total Revenue
FY2025Q1
YoY :
+31.55%
-14.38M
Operating Profit
FY2025Q1
YoY :
+34.19%
-13.43M
Net Income after Tax
FY2025Q1
YoY :
-9.09%
-0.20
EPS - Diluted
FY2025Q1
YoY :
+63.61%
-12.79M
Free Cash Flow
FY2025Q1
YoY :
0.00%
100.00
Gross Profit Margin - %
FY2025Q1
YoY :
+45.07%
-7.28K
FCF Margin - %
FY2025Q1
YoY :
+152.38%
-12.32K
Net Margin - %

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
4
71.0K
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
1
5.4M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

CRDF News & Events

Events Timeline

2025-06-18 (ET)
2025-06-18
09:21:03
Cardiff Oncology to share CRDF-004 trial data on July 29
select
2025-06-17 (ET)
2025-06-17
16:10:23
Cardiff Oncology appoints Roger Sidhu as chief medical officer
select
2025-06-02 (ET)
2025-06-02
16:09:15
Cardiff Oncology 'highly encouraged' by onvansertib data presented at ASCO
select
Sign Up For More Events

News

9.0
07-08Globenewswire
Global Oncology Breakthroughs Being Fueled by Advancements in Clinical Trials and New Therapies
4.0
06-24Benzinga
This MakeMyTrip Analyst Turns Bullish; Here Are Top 3 Upgrades For Tuesday
4.0
06-24Benzinga
This Amylyx Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday
Sign Up For More News

FAQ

arrow icon

What is Cardiff Oncology Inc (CRDF) stock price today?

The current price of CRDF is 4.14 USD — it has decreased -3.5 % in the last trading day.

arrow icon

What is Cardiff Oncology Inc (CRDF)'s business?

arrow icon

What is the price predicton of CRDF Stock?

arrow icon

What is Cardiff Oncology Inc (CRDF)'s revenue for the last quarter?

arrow icon

What is Cardiff Oncology Inc (CRDF)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Cardiff Oncology Inc (CRDF)'s fundamentals?

arrow icon

How many employees does Cardiff Oncology Inc (CRDF). have?

arrow icon

What is Cardiff Oncology Inc (CRDF) market cap?